Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) price target has been reduced by Baird due to the company’s announcement management decided that its exploration of strategic alternatives was unable to produce a sale or merger of the company. The firm has removed the takeout premium and thinks that investors will likely see the company as a long term investment with a conservative valuation. Shares have an Outperform rating.
Red Hat, Inc. (NYSE:RHT) price target has been increased by Susquehanna after its Q3 results due to its efforts to better tie partner channels,stable demand for products, and its ability to perform well despite economic conditions. The firm gives shares a Positive rating.
Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.
EQT Corporation (NYSE:EQT) announced its agreement to transfer its natural gas distribution business to Peoples Natural Gas, causing BMO Capital to say that the deal’s valuation was much higher than its previous estimate. Furthermore, the firm is convinced that the company now has the ability to achieve 30 percent or higher production growth in 2013, and it keeps its Outperform rating on the stock.
Herbalife Ltd. (NYSE:HLF): Investor Bill Ackman revealed that there was a large short interest in Herbalife, and he also presented evidence which he claimed proves that the company is a pyramid scheme. This has caused DA Davidson to stated that there is real demand for the company’s product. However, the firm doesn’t agree with Ackman’s statement that the company is a pyramid scheme which will collapse, and it keeps its Buy rating on the stock.
Baker (Michael) Corporation (AMEX:BKR): According to FBR Capital, Michael Baker shareholders could approve the $24.25 per share takeover offer from KS International, if it shows that it is credible, considering the fact that the company does not have a CEO or strategic direction. FBR does believe that a strategic buyer potentially may be willing to pay more than $30 per share for Michael Baker considering its possible cost synergies. The firm reiterates its Market Perform rating and a $25 price target on the stock.
Investing Insights: Is DuPont’s Stock a Buy Now?